Deconstruction of Medulloblastoma Cellular Heterogeneity Reveals Differences between the Most Highly Invasive and Self-Renewing Phenotypes

Abstract

Medulloblastoma (MB) is the most common malignant primary pediatric brain tumor. Major research efforts have focused on characterizing and targeting putative brain tumor stem or propagating cell populations from the tumor mass. However, less is known about the relationship between these cells and highly invasive MB cells that evade current therapies. Here, we dissected MB cellular heterogeneity and directly compared invasion and self-renewal. Analysis of higher versus lower self-renewing tumor spheres and stationary versus migrating adherent MB cells revealed differential expression of the cell surface markers CD271 [p75 neurotrophin receptor (p75NTR)] and CD133. Cell sorting demonstrated that CD271 selects for subpopulations with a higher capacity for self-renewal, whereas CD133 selects for cells exhibiting increased invasion in vitro. CD271 expression is higher in human fetal cerebellum and primary samples of the Shh MB molecular variant and lower in the more aggressive, invasive group 3 and 4 subgroups. Global gene expression analysis of higher versus lower self-renewing MB tumor spheres revealed down-regulation of a cell movement transcription program in the higher self-renewing state and a novel potential role for axon guidance signaling in MB-propagating cells. We have identified a cell surface signature based on CD133/CD271 expression that selects for MB cells with a higher self-renewal potential or invasive capacity in vitro. Our study underscores a previously unappreciated role for CD271 in selecting for MB cell phenotypes and suggests that successful treatment of pediatric brain tumors requires concomitant targeting of a spectrum of transitioning self-renewing and highly infiltrative cell subpopulations.

Neoplasia (2013) 15, 384–398

Abbreviations: MB, medulloblastoma; TPC, tumor-propagating cell; BTPC, brain tumor-propagating cell; GBM, glioblastoma multiforme

Address all correspondence to: Dr Tamra E. Werbowetski-Ogilvie, Regenerative Medicine Program, Department of Biochemistry and Medical Genetics, University of Manitoba, 611-745 Bannatyne Avenue, Winnipeg, Manitoba, Canada, R3E 0J9. E-mail: ogilvie@cc.umanitoba.ca

1This work was funded by the Brain Tumour Foundation of Canada, the Health Sciences Centre Foundation, and the Manitoba Health Research Council. T.E.W.-O. holds a Canada Research Chair in Human Stem Cells and Neuro-oncology. M.R.D.B. holds a Canada Research Chair in Developmental Neuropathology. The authors declare no conflict of interest.

2This article refers to supplementary materials, which are designated by Tables W1 to W4 and Figures W1 to W3 and are available online at www.neoplasia.com.

3These authors contributed equally to this work.

Received 8 January 2013; Revised 5 February 2013; Accepted 6 February 2013

Copyright © 2013 Neoplasia Press, Inc. All rights reserved 1522-8002/13/$25.00
DOI 10.1593/neo.13148
**Introduction**

Medulloblastoma (MB) is the most common malignant primary pediatric brain tumor [1,2]. Classified as grade IV embryonal tumors of the central nervous system by the World Health Organization, MBs are derived from the neuronal lineage and exhibit dysregulation of several pathways associated with primitive neuroectoderm development including Wnt, Hedgehog, and Notch signaling [1,2]. Following surgery and treatment with chemotherapy and radiation, MBs often recur as a consequence of tumor cell infiltration into normal tissue and frequent metastasis through the cerebral spinal fluid [1–3]. Despite numerous advances in understanding the molecular basis for the malignant state and a 5-year survival rate of 60% to 70% [1], children with MB suffer from permanent cognitive and physical dysfunction attributed to the impact of toxic therapies on their developing nervous system [1].

Cancer stem cell theory suggests that a rare subpopulation of cells exhibit stem cell properties such as self-renewal capacity and multilineage differentiation [4,5]. These cancer stem cells or tumor-propagating cells (TPCs) would ultimately drive tumorigenesis and must be specifically targeted to abrogate malignant progression. Singh et al. demonstrated that a small subpopulation of brain tumor cells that express CD133 cell surface marker exhibit enhanced self-renewal capacity [6,7]. This work firmly established the existence of a “stem cell–like” phenotype within malignant brain tumors. However, more recent studies have shown that CD133– and CD133+ cells exhibit self-renewal capacity, while CD133– cells can generate more aggressive tumors in vitro [8–12]. Other studies have demonstrated that the cell surface marker CD15/SSEA1 selects for MB TPC populations in murine models [13,14]. Given the wide expression of CD133 in many tissues, it will be necessary to break down the heterogeneity within CD133+/– populations to identify other markers that also select for aggressive phenotypes. This is further complicated by recent demonstrations that interconversion of cancer cells between various differentiation states enables reestablishment of cellular equilibrium irrespective of the cell surface markers used to sort subpopulations [15]. Indeed, sorted cell fractions are not static and will inevitably give rise to other phenotypes in response to appropriate microenvironmental cues.

Most work on malignant brain tumor cell invasion and TPCs has been mutually exclusive despite the fact that TPCs and invasive cells share many cellular and molecular features including resistance to radiation and chemotherapy [16–22]. While some recent studies have directly addressed the relationship between invasive carcinoma cells and TPC populations [23,24], the specific relationship between TPCs and invasion in brain tumors is less concrete. CD133 has typically been used as a putative brain tumor–propagating cell (BTCP) marker [7]; however, recent work has shown that CD133– cells display more aggressive behavior than the CD133+ cells associated with “stem cell” function [9,12]. Chen et al. demonstrated that a more primitive CD133–subpopulation of glioblastoma multiforme (GBM) cells gives rise to both CD133– and CD133+ subsets. Further validating this work is the finding that GBM stem cell populations selected on the basis of “side population” or Hoechst 33342 dye exclusion actually exhibit decreased migration [25]. In contrast, other reports have shown that invasive and tumor mass or “core” GBM cells exhibit self-renewal capacity and stem cell marker expression; however, the stem cell features are more pronounced in the invasive population [26].

To date, there are no studies directly examining the specific relationship between BTPCs and the highly invasive subpopulation in pediatric brain tumor cells. Here, we tested the hypothesis that dissection of MB cellular heterogeneity would reveal phenotypic differences between the highly self-renewing and invasive phenotypes. To this end, we deconstructed heterogeneous MB cultures and identified novel functional relationships among cells expressing CD133 and CD271 using an in vitro model system. Higher self-renewing cells exhibit a CD271+; CD133– cell surface signature, whereas a highly motile cell displays CD271–; CD133+ phenotype. This was supported by down-regulation of the cell motility transcription program in our highly self-renewing tumor spheres in stem cell conditions. Our study has identified a previously unappreciated role for CD271 in selecting for MB cell types and suggests that successful treatment of MB will require targeting of transitioning self-renewing and highly infiltrative MB subpopulations expressing several phenotypic markers.

**Materials and Methods**

**Cell Culture and Maintenance**

Daoy human MB cells (originally derived from a desmoplastic cerebellar MB) and D283 cells were purchased from the American Type Culture Collection (ATCC, Rockville, MD). Cells were cultured in Eagle’s minimum essential media (EMEM) (ATCC) containing 10% FBS (Fisher Scientific, Ottawa, Ontario). Upon reaching confluency, cells were dissociated in Accutase (Invitrogen, Burlington, Ontario) and passed 1:15. Neural precursors from normal human embryonic stem cells called hENs and their transformed MB-like derivatives (t-hENs) were cultured as previously described [27]. Briefly, cells were dissociated for 5 minutes in Accutase and replated onto poly-l-lysine/laminin–coated plates (BD Biosciences, Mississauga, Ontario) in neural proliferation media [Dulbecco’s modified Eagle’s medium (DMEM)/F12 supplemented with 1% N2 (Gibco, Burlington, Ontario), 1% B27 (Gibco), 20 ng/ml epidermal growth factor (EGF; R&D Systems, Minneapolis, MN), and 20 ng/ml basic fibroblast growth factor (bFGF)]. Cells were passaged every 5 days with media changes every 3 days.

For subclone expansion, Daoy MB cells were dissociated and resuspended in Dulbecco’s phosphate-buffered saline (DPBS; Fisher Scientific) containing 0.5% FBS. A MoFlo XDP (Beckman Coulter, Inc, Mississauga, Ontario) cell sorter was used to deposit single Daoy cells into each well of a 96-well plate. These cells were subsequently cultured in EMEM with 10% FBS and expanded. Aliquots of 2.5 × 10^5 cells were prepared as hanging drops in 20 μl as previously described [28,29]. Hanging drops were incubated for 3 days to form spheroids and then transferred to collagen type I gels (VWR, Mississauga, Ontario) prepared as previously described [29]. Following collagen gelation at 37°C, embedded spheroids were then overlain with EMEM containing 10% FBS. Spheroid measurements were taken at day 0 and invasion was measured at 72 hours (day 3) using a Zeiss Primo Vert microscope with micrometer. Individual Daoy subclones were characterized on the basis of their invasive capacity.

**Flow Cytometry Cell Surface Marker Screen**

Daoy subclones were dissociated, washed with DPBS, and cultured as tumor spheres in ultralow attachment plates with DMEM/F12 containing 1% B27, 1% N2, 20 ng/ml EGF, and 20 ng/ml bFGF. On day 4, tumor spheres were fed by removal and replacement of 1 ml of media. On day 7, Daoy tumor spheres were dissociated, washed, and resuspended in DPBS containing 0.5% FBS. Cells were counted using an automated cell counter (Bio-Rad, Mississauga, Ontario) or hemocytometer. Cells were then stained with one of the
following antibodies: CD44-FITC, CD30-FITC, CD184-PE, CD26-FITC, CD271–Alexa Fluor 647, CD133-PE, CD15-APC, or CD24-PE. All antibodies were obtained from BD Biosciences, with the exception of CD133 (Miltenyi Biotec, Cambridge, MA). Flow cytometry was performed on the MoFlo XDP cell sorter and analyzed using FlowJo software (Tree Star Inc, Ashland, OR).

**Daoy Core and Migrating Cell Dissections**

Daoy MB cells were prepared as hanging drops as previously described [28,29]. After 3 days of incubation, resulting spheroids were transferred into a plate containing EMEM with 10% FBS. Spheroids were incubated for 2 days, at which time the “core” was mechanically dissected from the migrating cells. The dissected cores as well as the remaining migrating cells were dissociated separately, resuspended in DPBS with 0.5% FBS, and stained with antibodies for CD44, CD30, CD184, CD26, CD271, CD133, CD15, and CD24 for analysis by flow cytometry.

**Fluorescence-activated Cell Sorting**

Day 7 passage 2 Daoy tumor spheres were pooled, dissociated, and counted using an automatic cell counter and stained for CD133 and CD271. Sort samples were also stained with 7AAD viability dye (Beckman Coulter, Inc.). Cells were sorted on the basis of CD133/CD271 using a MoFlo XDP cell sorter. Analysis of cell sorting was performed using FlowJo software. Collected cell fractions were centrifuged and counted for subsequent functional assays.

For tumor sphere assays, aliquots of 2500 cells from each subpopulation were plated in a 24-well low attachment plates in DMEM/F12 containing 1% B27, 1% N2, 20 ng/ml EGF, and 20 ng/ml bFGF. Cells were incubated for 5 days, after which tumor spheres were counted. Tumor spheres from each population were then counted and replated in aliquots of 2500 cells for secondary tumor sphere assays.

For cumulative cell counts, aliquots of 2500 cells from each subpopulation were plated in a 24-well tissue culture plate in EMEM containing 10% FBS. Cells were fed on day 3, and on day 4, they were dissociated and counted using a hemocytometer to obtain cumulative cell counts.

For invasion assays, aliquots of 1.5 x 10^5 to 2.5 x 10^5 of sorted cell fractions were prepared as hanging drops and embedded in a type I collagen matrix as described. Measurements were taken on day 0 and day 3. Images were taken using a Nikon Eclipse TS100 microscope and Nikon DS-Fi1 Digital Sight camera (Nikon, Mississauga, Ontario).

**Intracerebral Transplantations and Histology**

The University of Minnesota Animal Care Committee approved all procedures and protocols. CD271+/CD133−, CD271+/CD133−, and unsorted Daoy tumor spheres were intracerebrally injected into non-obese diabetic severe combined immunodeficient (NOD/SCID) mice as previously described [7,27]. Briefly, mice were anesthetized and injected in the right frontal lobe with biologic replicates consisting of 2 x 10^5 CD271+/CD133−, CD271+/CD133−, and unsorted Daoy tumor spheres. After 7.5 weeks, animals were perfused with formalin and the brains were extracted, placed in formalin for 2 to 7 days, embedded in paraffin, and then sectioned (5-μm thickness). Sections were dehydrated in xylene and rehydrated through a graded series of alcohol concentrations. Samples were stained with hematoxylin and eosin. Slides were mounted and imaged using an EVOS xl core microscope (AMG, Seattle, WA). Malignant cell growth was scored, from a scale of 0 to 3, where 0 = no malignant cells with certainty, 1 = indicates rare clusters of malignant cells confined to subarachnoid compartment, 2 = malignant cells in subarachnoid compartment and infiltrating perivascular spaces, and 3 = features in 2, in addition to tumor nodules growing in other areas of the brain or cerebellum. For each tumor sample, two slides containing six to seven brain sections were scored and averaged to obtain a grade. Slides were assessed by a neuropathologist who was blinded to cellular identity.

**5-Fluorouracil Treatment**

Daoy passage 1 tumor spheres were plated in six-well low attachment plates at a cell density of 1 x 10^4 cells per well, in duplicate. Concentrations of 0.5, 1.0, and 2.5 μg/ml 5-fluorouracil (5-FU; Sigma, Oakville, Ontario) as well as a DMSO control were used. Cells were plated on day 0, and then after 7 days, samples were dissociated and half were collected for flow cytometry analysis of CD133/CD271 or viability using the Annexin V Apoptosis Kit (BD Biosciences). The remaining samples were replated in fresh neural precursor media or fresh neural precursor media with various concentrations of 5-FU. Samples were then collected and analyzed again at day 14.

**Quantitative Reverse Transcription–Polymerase Chain Reaction**

Core and migrating cell populations were subjected to quantitative polymerase chain reaction (qPCR) analysis of Otx2, Sox1, βIII tubulin, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, and ephrin B2 transcript levels. Total RNA was extracted using the AllPrep DNA/RNA Mini Kit (Qiagen, Mississauga, Ontario) according to the manufacturer’s guidelines. First-strand cDNA was synthesized using the SuperScript III First Strand Synthesis System (Invitrogen). The following PCR conditions were used: 50°C for 2 minutes, 95°C for 2 minutes, and 40 cycles of 95°C for 15 seconds and 60°C for 30 seconds. qPCR was conducted using Platinum SYBR Green qPCR SuperMix-UDG (Invitrogen) or GoTaq qPCR Master Mix (Fisher Scientific) and performed on an Mx3000P (Stratagene, Santa Clara, CA) qPCR system. All values were normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Specific primer sequences for each gene are listed in Table W4.

**Global Gene Expression Profiling**

Total RNA was isolated from higher versus lower self-renewing Daoy MB tumor spheres, using the All-in-One Purification Kit (Norgen Biotek, Thorold, Ontario) according to the manufacturer’s instructions. RNA amplification and GeneChip 3’ oligonucleotide microarray hybridization and processing were performed by the London Regional Genomics Centre (Robarts Research Institute, London, Ontario) according to the manufacturer’s protocols (Affymetrix, Santa Clara, CA). N = 3 biologic replicates for the higher versus lower Daoy MB tumor spheres were analyzed. Ten micrograms of cRNA was labeled and hybridized to the Affymetrix Human Gene 1.0 ST chips. Expression signals were scanned on an Affymetrix GeneChip Scanner and data extraction was performed using Affymetrix AGCC software. Data normalization and analysis was performed using Chip software. Hierarchical clustering using Pearson correlation coefficients was performed on the normalized data. Differentially expressed genes were analyzed using Ingenuity Pathway Analysis (Redwood City, CA). Transcripts dysregulated at least two-fold (upregulated or downregulated) in the higher versus lower self-renewing Daoy tumor spheres with a P < .05 were considered significant.

**Exon Array Profiling**

Affymetrix Human 1.0 exon array profiling was used to examine expression of CD271 (p75/NTR) in 14 normal cerebellar samples
Expression of CD271 (p75/NGFR) across all samples is presented in boxplot format as log2-transformed signal intensity.

Statistical Analysis

All tests were performed using Prism 5 software (GraphPad Software, La Jolla, CA) or SPSS Statistics (IBM, Armonk, NY). Descriptive statistics were used to determine significant differences including mean and SEM along with one-way analyses of variance, independent sample two-tailed t tests, and Tukey’s test for multiple comparisons. P values less than .05 were considered significant.

Results

MB Subclones Exhibit Variable Morphology, Invasiveness, and Self-Renewal Capacity

To evaluate MB cellular heterogeneity, we first derived subclones from the Daoy MB cell line. Adherent Daoy cultures were dissociated and single-cell derived clonal expansion of Daoy cells after sorting. Expanded clones were cultured as hanging drop aggregates for 3 days and then placed into three-dimensional type I collagen gels to follow invasion for 72 hours. Representative images of monolayer adherent cultures and hanging drop aggregates from Daoy subclones. Note that some clones exhibited an elongated morphology (B) and others displayed a rounded or ruffled (C) appearance. Scale bar, 100 μm. When placed in collagen gels, hanging drops from elongated clones exhibited a higher invasive capacity (D), whereas hanging drops derived from rounded clones typically grew in collagen but only minimally invaded (E). Scale bar, 250 μm. (F) Invasive capacity of all 21 subclones derived from the parental Daoy MB cell line. Error bars, SEM.
into a single-cell suspension and single cells were sorted and individually plated (Figure 1A). A expanded and then cultured aggregate preparation [29] (Figure 1, A–C). Aggregate spheroids were implanted into collagen gels, and invasion was measured after 72 hours (Figure 1, A, D, and E). The 21 subclones exhibited morphologic heterogeneity with some displaying an elongated appearance (Figure 1B), while others exhibit a rounded or ruffled morphology (Figure 1C). The elongated subclones demonstrated a higher invasive capacity than the rounded clones (Figure 1, D and E). In addition, there was a six-fold invasion difference between the clones exhibiting the highest and least invasive capacity (Figure 1F). The most (N = 5 independent subclones) and least (N = 3 independent subclones) invasive subclones were then plated into neural stem cell (NSC) culture at a concentration of 20,000 cells/well (5 cells/μl) to examine self-renewal. In bulk culture, tumor spheres derived from the most invasive subclones exhibited a significantly higher self-renewal capacity when placed in NSC culture, spheres and this passages (Figure 2A). After invasive subclones began subsequently expanded as adherent cultures (Figure 2, B and C). Tumor spheres from the most invasive subclones did not adhere and continued to maintain their self-renewal capacity. Together, these results demonstrate that MB cultures exhibit morphologic and cellular heterogeneity. Although subcloning leads to independent, phenotypically distinct subcultures of Daoy cells, there are likely still subpopulations or lineages of cells within each of these clonally derived lines that could separately account for the self-renewing and invasive behaviors. To further define these subpopulations, we must perform expression profiling to determine which cell surface markers may select for highly self-renewing or invasive phenotypes.

**Tumor Spheres Displaying Higher versus Lower Self-Renewal Capacity Exhibit Differential Expression of CD271**

Tumor spheres derived from our MB subclones displayed differential self-renewal capacity. Therefore, we wanted to test whether these same tumor spheres also exhibit changes in cell surface marker expression. Passage 0 tumor spheres from subclones displaying higher self-renewal (N = 5 independent subclones) versus lower self-renewal (N = 3 independent subclones) were comparatively screened for the presence of cell surface markers already known to play a role in neural lineage specification, BTPCs, and/or tumor cell metastasis (Figure 2, D–L). Comparative analysis of higher versus lower self-renewing tumor spheres using flow cytometry revealed significant differential expression of CD271 (p75NTR; Figure 2I), CD24 and CD133 also showed differential expression; however, the results were not significant (Figure 2, J and L). Breakdown of higher versus lower self-renewing tumor spheres into individual subclones revealed that four of five highly self-renewing subclones tested exhibited elevated levels of CD271, whereas all three lower self-renewing subclones tested expressed very low levels (Figure 2M). To assess whether CD271, CD133, and CD24 are enriched in tumor sphere culture, we examined expression levels in confluent adherent cultures with 10% FBS relative to passage 1 and passage 2 tumor spheres (Figure 2, N and O). CD271 and CD133 are elevated following enrichment for the stem cell–like phenotype (Figure 2N). In fact, CD271 levels are enriched 77-fold, even higher than the 36-fold enrichment seen with CD133 (Figure 2N). In contrast, CD24 exhibits a rapid decline over subsequent tumor sphere passages (Figure 2O). To determine whether CD271 and CD133 are also enriched in other MB cell lines, we examined expression levels in adherent versus tumor sphere culture from D283 MB cells. Compared to adherent cultures, D283 tumor spheres exhibit a small but significant and consistent increase in CD271 expression (Figure W1A). Interestingly, CD133 levels declined following culture of D283 cells as tumors spheres (Figure W1B). We also examined CD271 and CD133 levels in our recently described transformed neural precursor model of MB [27]. Relative to normal human embryonic neural precursors (hENs), neoplastic or transformed human embryonic neural precursors (t-hENs), exhibit a higher self-renewal capacity in vitro and an MB phenotype in vitro. A comparison of t-hEN versus hEN cultures revealed a significant increase in CD271 levels in t-hEN MB–like cells (Figure W1C). CD133 levels exhibited wide variation between trials and overall remain unchanged (Figure W1D). Together, these results demonstrate that CD133 patterns vary between cell lines and support recent findings suggesting that CD133 should not be used as an exclusive marker for selection of BTPCs [8–12]. Interestingly, in the cell lines tested, CD271 is consistently higher in tumor sphere culture or MB cells with a higher self-renewal capacity. CD271 may therefore play a novel role in selecting for MB TPCs in vitro.

**Migrating MB Cells Exhibit Decreased CD271/CD24 and Increased CD133 Expression**

Tumor spheres derived from the higher versus lower self-renewing MB subclones exhibit differential expression of CD271. These results may be attributed to the differences in self-renewal between subclones specifically in tumor sphere culture or may be linked to the differential invasive capacities of the parental cultures when placed in collagen gels. It is unclear whether changing the biologic context will also change the expression patterns of these cell surface markers. To test the possibility that cell surface markers exhibit differential expression...
patterns in other biologic assays, we conducted aggregates to separate
the stationary cells (Figure 3, A and B). MB hanging drop aggregates
from the parental Daoy cell line were allowed to adhere to a cell culture
plate surface and individual cells migrated out from the center over a
48-hour period. The aggregate core was mechanically dissected and
both “core” and “migrating” cell populations were dissociated and
subjected to our eight-cell surface marker antibody screen. CD271
was significantly different between core and migrating cell populations.
In these cell conditions, CD24 and CD133 were also significantly dif-
ferent (Figure 3, C–F). Interestingly, CD271/CD24 levels were higher
in the core cell population, whereas CD133 was higher in the migrating
cells (Figure 3, C–F). In addition, we examined transcript levels of neu-
ral lineage markers by qPCR and found that the primitive neuroecto-
derm marker Otx2 was significantly higher in the core cell population,
while Sox1 levels remain unchanged (Figure 3K). Interestingly, the
more differentiated βIII tubulin was significantly lower in this core pop-
ulation (Figure 3K). This was supported at the protein level by flow
cytometry studies demonstrating lower βIII tubulin in the core popu-
lation (data not shown). However, nestin levels were not significantly
different (data not shown). Taken together, these results demonstrate
that lower CD271/CD24 and higher CD133 levels “mark” a migrating
MB versus a core cell and that migrating MB cells may represent a
slightly more differentiated state. Differential expression patterns in
the tumor spheres (Figure 2) may therefore reflect changes in self-re-
newal capacity between the MB subclones. These seemingly opposing
results can be explained by the biologic context or cellular conditions
the MB cells are subjected to. Our results point to novel functional re-
lationships among cells expressing CD271, CD24, and CD133. How-
ever, as CD271 was significantly and consistently elevated in higher
self-renewing tumor spheres and CD133 has been widely implicated
in brain tumorigenesis, we chose to further pursue the relationship be-
tween CD271 and CD133 for additional experiments.

CD271 Selects for MB Cells with Increased Self-Renewal while
CD133 Selects for Cells Exhibiting Higher Invasion

From our screening data, we predicted that CD271 and CD133
would mark cells displaying differences in cellular properties. To test
this hypothesis, we used fluorescence-activated cell sorting tumor
spheres based CD271 Figure 4, these experiments, procedure than
D283, hEN, and t-hEN cell lines. Purified subpopulations were then
subjected to tumor sphere assays, cumulative cell counts in adherent
culture, and invasion assays in collagen gels (Figure 4A).

Sorted MB cells from tumor spheres were replated in NSC culture
at a density of 2500 cells/well (2.5 cells/µl) and the number of tumor
spheres was counted after 5 days (Figure 4, C and D). Cell populations
positive for CD271 (CD133+/CD271+ and CD133+/CD271+) gen-
erated a higher number of tumor spheres over passage (Figure 4, C and
D). CD133−/CD271+ cells displayed the highest enrichment of tumor
spheres with a more than three-fold increase in tumor sphere number
from passages 1 to 2. Our results demonstrate that CD271 select for
MB cells with the highest self-renewal capacity in vitro. These data are
consistent with our findings that both CD271 and CD133 are elevated
in stem cell culture (Figure 2N); however, CD271, with an even higher
enrichment in Daoy cells, may better select for MB-propagating cells
in vitro.

Sorted subpopulations from MB tumor spheres were also sub-
jected to cell count assays. Briefly, 2500 cells from sorted populations
were plated in adherent conditions in media containing 10% FBS,
and cumulative cell counts were taken after 4 days. Our results dem-
onestrate that the CD133−/CD271− population exhibits a significantly
higher number of cells after 4 days (Figure 4E). Interestingly, the other
three subpopulations exhibit a total cell number lower than the starting
cell population, suggesting a possible survival effect in adherent culture.
These results demonstrate that the fractions exhibiting an elevated
capacity for self-renewal are not the same as those with the highest
cumulative cell number overtime.

In contrast to our results for self-renewal, when sorted MB sub-
populations were cultured as hanging drop aggregates and then
placed into collagen gel invasion assays, the CD133+/CD271− sub-
population demonstrated a higher invasive capacity (Figure 4, F and
G). Invasion was always highest in the MB subpopulations that
exhibit a lower self-renewal capacity. In addition, we noted a distinct
invasion pattern between the CD133+/CD271− and CD133−/CD271−
cells with the former invading as a collective wave of cells,
whereas the latter is characterized by leading elongated cells and a
stream of less invasive cells lagging behind (Figure 4F). While the
invasion increase in CD133+/CD271− cells was not significantly dif-
ferent from the other subpopulations, it should be noted that we were
often unable to obtain high CD133+ cell numbers and, consequently,
were only able to generate two complete data sets with replicates from
all four subpopulations. However, these trends support our core versus
migrating cell data (Figure 3), where CD271 levels are higher in the
core cells and CD133 expression is elevated in migrating cells. Collect-
ively, our data demonstrate that combinatorial expression of CD271
and CD133 enables selection for MB cells displaying variations in
cellular properties.

CD271+ MB Cells Exhibit Chemoresistance at
Low Concentrations

It is well documented that both BTTPCs and highly invasive cells
are resistant to conventional therapies such as chemotherapy and radi-
ation [16–22]. However, the majority of these studies were conducted
in GBM models, and less is known about the effect of therapeutic treat-
ments on putative MB self-renewing cells. To investigate the effect of
chemotherapeutic agents on MB subpopulations treated MB tumor days
Figure 5, A and increased apoptosis enrichment of the CD133−/CD271−
subpopulation at the lowest concentration of 5-FU (Figure 5,
M–Q). After 14 days, the CD133−/CD271− fraction that exhibits a
higher capacity for self-renewal is nearly doubled (Figure 5Q). At higher
concentrations, the CD133−/CD271− subpopulation is significantly
decreased but is still present after 14 days (Figure 5, O–Q). These
patterns are also sustained after 21 days of treatment (data not shown).
Taken together, these results demonstrate that chemotherapeutic agents
fail to eliminate the cell population with the highest capacity for self-
renewal and suggest that in our MB model system, the CD133−/CD271+
may represent a drug-resistant phenotype.

CD133−/CD271+ Cells Exhibit Tumor-Initiating
Capacity In Vivo

We have shown that CD271 has a novel role in selecting for highly
self-renewing MB cells in vitro. We hypothesized that these cells
would also exhibit tumor-initiating capacity in vivo. To test this, we
specifically sorted CD133−/CD271+ and CD133+/CD271− cells from
MB tumor spheres and injected $2 \times 10^5$ cells for each subpopulation
($N = 3$ CD133−/CD271+ and $N = 4$ CD133+/CD271−) along with
unsorted cells from MB tumor spheres ($N = 4$) intracranially into mice.
After 5 weeks (36 ± 1 days), animals injected with CD133−/CD271+
cells started to exhibit neurologic signs of potential tumor head (Figure 6A). While unsorted tumor sphere cells also exhibited these neurologic signs, this was typically delayed. The average time between injection and neurologic signs was 41 ± 2.5 days for CD133−/CD271− cells and 44 ± 2 days for unsorted MB tumor sphere cells (Figure 6A). After 7.5 weeks, mice injected with unsorted MB tumor spheres displayed rare clusters of malignant cells typically confined to the subarachnoid space (Figure 6, C and F). However, mice injected with

![Image](image-url)

**Figure 3.** Comparative cell surface marker expression from “core” versus “migrating” MB cells reveals differential expression of CD271, CD133, and CD24. (A, B) Images of an MB hanging drop aggregate before (A) and after (B) manual “core” dissection. Scale bar, 250 μm. (C–J) Cell surface marker antibody screen on the “core” versus “migrating” cells from MB aggregates 48 hours after attachment. Cell surface markers were chosen on the basis of their proposed role in neural lineage specification, brain tumor stem cell self-renewal, and tumor cell invasion. Error bars, SEM; *P < .05; N = 4 and N = 3 independent experiments. (K) qPCR analysis of selected neural stem cell/primitive neural transcripts and differentiated neuronal markers in “core” versus “migrating” Daoy MB cells. Error bars, SEM; *P < .05.
CD133−/CD271+ cells displayed the most prominent tumorigenic features (Figure 6, B, D, and G), characterized by a dense mass of malignant cells exhibiting a high nuclear-to-cytoplasmic ratio, abundant mitotic and apoptotic figures, diffuse infiltration of malignant cells in the subarachnoid compartment at the base of the brain, and intense infiltration into the brain along perivascular spaces (Figure 6, B, D, and G). This was associated with hydrocephalus due to obstructed cerebrospinal fluid flow. Mice injected with CD133−/CD271− cells also displayed tumorigenic features (Figure 6, B, E, and H); however, infiltration along perivascular spaces was minimal in comparison (Figure 6, E and H). Together, these results demonstrate that CD271+ cells exhibit the capacity for tumor initiation in vivo.

The ability of both CD133−/CD271+ and CD133−/CD271− cells to initiate tumor formation may reflect 1) each individual sorted subpopulation’s capacity for tumor initiation or 2) a subpopulation’s ability to reestablish heterogeneity and all cell phenotypes following...
Figure 5. 5-FU treatment of MB tumor spheres leads to an enrichment of the CD133−/CD271+ subpopulation. (A–H) Representative images of Daoy MB tumor spheres treated with 0.5, 1.0, and 2.5 μg/ml 5-FU relative to DMSO controls after 7 days (A–D) and 14 days (E–H). Scale bar, 250 μm. (I–L) Annexin V/7AAD analysis of Daoy MB tumor spheres treated with 0.5, 1.0, and 2.5 μg/ml 5-FU relative to DMSO controls after 14 days. (M–Q) Quantification of the effect of 5-FU on CD133/CD271 subpopulations after 14 days. (M–P) Representative flow cytometry images of CD133/CD271 expression following treatment with DMSO and 0.5, 1.0, and 2.5 μg/ml 5-FU. (Q) Quantification of the frequency of specific CD133/CD271 subpopulations following treatment with 5-FU. Error bars, SEM; **P < .01, ***P < .001; N = 4 independent experiments.
**B. Tumor cell grading in recipient mice**

<table>
<thead>
<tr>
<th>Unsorsed</th>
<th>CD133-/CD271+</th>
<th>CD133-/CD271-</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>0</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>2</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>1</td>
<td>0</td>
<td></td>
</tr>
</tbody>
</table>

Mean: 1 Mean: 1.7 Mean: 1.3

---

**C. Unsorsed Tumorspheres**

**D. CD133-/CD271+**

**E. CD133-/CD271-**

---

**F.**

**G.**

**H.**

---

**I. Parental tumorsphere cultures**

- CD271+ CD271- CD133+ CD133-
- 1.1% 1.6% 27.3% 70%

---

**J. CD133+/CD271- sorted**

- 0.7% 8.9% 8.4% 83.2%

---

**K. CD133+/CD271+ sorted**

- 1.1% 2.16% 25.4% 71.4%

---

**L. CD133+/CD271- sorted**

- 0.3% 3.2% 5.7% 90.8%
intracranial transplantation. To test these hypotheses, we recultured $1 \times 10^4$ sorted CD133+/CD271−, CD133−/CD271+, and CD133−/CD271− cells as tumor spheres and analyzed CD271 and CD133 levels after 6 days. CD133+/CD271+ cells consistently recapitulated the distribution of parental tumor sphere culture phenotypes (Figure 6, I–L). In particular, the >10:1 ratio of CD133+/CD271+ to CD133+/CD271− cells was maintained. Both CD133+/CD271− and CD133−/CD271− cells were also able to generate all four subpopulations, albeit at different ratios with a notable decline in CD271 (Figure 6, I–L). Together, these results demonstrate that sorted subpopulations reset phenotypic equilibrium in culture. This reestablishment could lead to tumor initiation from the different subpopulations in vivo. Our data support the idea that cell subpopulations can transition between higher self-renewing and invasive states.

**CD271 Levels Are Higher in the Shh MB Molecular Variant and Fetal Cerebellum and Lowest in the More Aggressive, Invasive Group 3 and 4 Subgroups**

Recent studies have demonstrated that MB is divided into distinct molecular subtypes [31]. In particular, a Wnt pathway variant, a Shh pathway variant, and highly aggressive, metastatic group 3 and 4 subgroups have been identified [30,31]. On the basis of the expression patterns of CD271 in vitro, we predicted that CD271 levels would be higher in the typically less aggressive Shh and Wnt variants relative to the invasive/metastatic group 3 and 4 subgroups. To test this hypothesis, we probed for expression of CD271 in an MB data set derived from exon array profiling of 111 primary MB and 14 normal human cerebellar samples (9 fetal cerebellum and 5 adult cerebellum). CD271 expression was significantly higher in fetal cerebellum and the Shh molecular variant cerebellum (Figure 7A). As and 4 (Figure 7A). While CD271 expression in the Wnt subgroup was higher than in groups 3 and 4, the levels were not significantly different. Overall, these results lend further support to the concept that CD271 levels are lower in the most invasive/metastatic phenotypes.

**Highly Self-Renewing MB Tumor Spheres Exhibit Down-Regulation of the Cell Motility Transcription Program**

Our screening and sorting results demonstrate CD271↑, CD133↓ in highly self-renewing tumor spheres but CD271↓, CD133↑ in migrating/invading cells. Even though the higher self-renewing tumor sphere subclones were derived from adherent cultures exhibiting elevated invasion in collagen gel assays, it is unclear whether cells in the “stem cell” or tumor sphere microenvironment exhibit the same capacity for cell motility. To address this, we conducted global gene expression analysis on higher versus lower self-renewing MB tumor spheres from independent subclones. Affymetrix analysis revealed that a total of 264 transcripts were significantly and differentially expressed between the higher versus lower self-renewing MB tumor spheres (Table W1). Eighty-four transcripts were associated with cellular movement, of which 67 (80%) were downregulated (Figure W2 and Table W2). On the basis of the directional changes and known function of the associated transcripts, cellular movement was predicted to be decreased in higher self-renewing tumor spheres (Table W3). Among the cellular movement transcripts, pathways (Table 1). In B signaling pathways, including the receptors EPBH1, EPBH3, and EPBH6 as well as the ligand ephrin B2 (Table 1).
The inverse but not mutually exclusive correlation between self-renewal and invasion is seemingly at odds with the positive relationship between our most highly invasive MB subclones and their self-renewal capacity depicted in Figure 2, A to C. These experiments were conducted in bulk culture and did not determine whether those cells that are invading are the same self-renewing TPCs that ultimately sustain tumor sphere cultures. In fact, molecular characterization of the highly self-renewing versus lower self-renewing tumor spheres from independent subclones revealed a global down-regulation of the cell motility transcription program in highly self-renewing tumor spheres. Even though the higher self-renewing tumor spheres were derived from adherent cultures exhibiting elevated invasion in collagen gel assays, when placed in tumor sphere culture, the cell movement program is downregulated. Therefore, changing the biologic context or microenvironment also changes gene expression patterns representative of a particular cell state. This is supported by our screening results demonstrating CD271↑, CD133↓ in highly self-renewing tumor spheres but CD271↓, CD133↑ in migrating cells. Indeed, these cell subpopulations are not in a "static" state and can transition between phenotypes to reestablish cellular heterogeneity. This concept was recently demonstrated by Gupta et al. [15] with an elegant series of experiments using breast cancer cell lines. Therefore, we cannot assume that a particular set of cell surface markers will only select for one specific tumor cell phenotype. Future studies will examine the epigenetic mechanisms that may be responsible for the suppression of the cell motility program in higher self-renewing MB tumor spheres.

CD271 is commonly referred to as p75 or p75NTR and is a member of the tumor necrosis factor receptor family [36]. The receptor normally functions in the development of the nervous system, including growth cone elongation and axon guidance. CD271 has proapoptotic and prosurvival effects, depending on the neurotrophin ligand [36]. Recently, this receptor has also been linked to glioblastoma

These results demonstrate that there is an overall down-regulation of a cell motility program in higher self-renewing MB tumor spheres and that dysregulated Eph-ephrin signaling may be involved in MB TPC function.

We have demonstrated differential expression of Eph-ephrin pathway ligands and receptors in the higher versus lower self-renewing tumor spheres; therefore, we also wanted to see whether this pathway is also dysregulated in MB core versus migrating cells. We examined transcript levels of the ephrin B2 ligand as well as the receptors EPHB1, B2, B3, B4, and B6 by qPCR. We found that the ligand ephrin B2 as well as the receptors EPHB1 and EPHB2 are significantly upregulated in the migrating versus the core cells, while the receptors EPHB3 and B4 are significantly downregulated (Figure W3, A–F). Together, our results demonstrate that the Eph-ephrin pathway is not only differentially expressed in tumor spheres with variable self-renewal capacity but also in migrating versus core MB cells. These data suggest that the Eph-ephrin pathway may play an important functional role in both MB TPCs and migration/invasion.

**Discussion**

In this study, we deconstructed MB cellular heterogeneity and identified a novel role for CD271 in enriching for a highly self-renewing MB phenotype. We propose a dynamic model (Figure 7B) whereby a highly self-renewing CD271↑, CD133↓ cell in the MB tumor core may help sustain tumorigenesis. Once a cell commits its metabolic machinery to migration and/or invasion, the levels of these cell surface markers change, and a highly motile cell will acquire a CD271↓, CD133↑ signature. As self-renewal and invasion are not mutually exclusive, this concept aligns with recent studies demonstrating that both CD133+ and CD133− cells exhibit BTPC function [8,9,11]. In addition, our work is also consistent with findings in glioblastoma that reveal a spectrum of self-renewing and aggressive cellular phenotypes that differentially express CD133 [12]. Highly self-renewing and invasive cells have also been shown to proliferate less. Therefore, it is not surprising that these subpopulations are distinct from those exhibiting the highest cumulative cell count in our study. However, it should be noted that the higher total cell number observed in CD133−/CD271− MB cells might be attributed to a variety of mechanisms including increased adhesion and/or survival upon replating of sorted subpopulations combined with possible differences in cell cycle properties. While we also observed some interesting trends with CD24, this cell surface marker was in fact downregulated in stem cell conditions relative to adherent cultures. This suggests that CD24 may mark an MB progenitor population and is supported by expression patterns during neural lineage specification where high levels of CD24 are observed in transit-amplifying cells [32] and differentiated neurons [33] and lower expression is seen in NSCs [34,35].

Table 1. Dysregulation of Neural Developmental Pathway Transcripts in the Higher versus Lower Self-Renewing MB Tumor Spheres.

<table>
<thead>
<tr>
<th>Entrez Gene Name</th>
<th>Gene Symbol</th>
<th>Fold change (Higher versus Lower Self-Renewing Tumor Spheres)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Myosin, light chain 1, alldy skeletal, fast</td>
<td>MYL1</td>
<td>4.2751</td>
</tr>
<tr>
<td>p21 protein (Cdc42/Rac)-activated kinase 3</td>
<td>PAK3</td>
<td>2.61359</td>
</tr>
<tr>
<td>Neurotrophic tyrosine kinase, receptor, type 2</td>
<td>NTRK2</td>
<td>2.44057</td>
</tr>
<tr>
<td><strong>EPH receptor B1</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Myosin light chain, phosphorylatable, fast skeletal muscle</td>
<td>MYL2</td>
<td>2.39499</td>
</tr>
<tr>
<td><strong>EPH receptor B3</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dihydropyrimidinidase-like 5</td>
<td>DPYSL5</td>
<td>2.06395</td>
</tr>
<tr>
<td>Tubulin, β4</td>
<td>TUBB4</td>
<td>2.02616</td>
</tr>
<tr>
<td><strong>EPH receptor B6</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patched 2</td>
<td>PTCCH2</td>
<td>-2.12875</td>
</tr>
<tr>
<td>Slit homolog 3 (Drosophila)</td>
<td>SLIT3</td>
<td>-2.57108</td>
</tr>
<tr>
<td>Ephrin-B2</td>
<td>EPHB2</td>
<td>-2.69877</td>
</tr>
<tr>
<td>Sema domain, immunoglobulin domain (fg), short basic domain, secreted, (semaphorin) 3C</td>
<td>SEMA3C</td>
<td>-2.8071</td>
</tr>
<tr>
<td>Sema domain, seven thrombospodin repeats (type 1 and type 1-like), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 5A</td>
<td>SEMA5A</td>
<td>-3.1147</td>
</tr>
</tbody>
</table>

Eph-ephrin signaling transcripts are in **bold**.
invasion [37] and could be targeted with the use of γ-secretase inhibitors [38]. CD271 is also present in MB as well as the external granular layer (EGL) and Purkinje layer in the developing human cerebellum but absent in the adult cerebellum [39]. On the basis of expression in both human fetal cerebellum and MB patient samples, the authors suggested that CD271 could be a predictor marker linked with more primitive cell populations [39]. Our primary patient MB and cerebellar sample data revealed the same CD271 patterns. Interestingly, studies have also demonstrated that CD271-positive cells in the EGL are negative for CD133 [39]. This suggests that an inverse relationship between these cell surface markers may also exist in the developing cerebellum. It has been shown that granular neural precursors from the cerebellar EGL are the cell of origin for the Shh-MB variant [40,41]. The EGL is present in fetal but not adult cerebellum, and therefore, it is not surprising that fetal cerebellar and Shh tumor samples display high CD271 levels. CD271 may be important for Shh-driven or desmoplastic MB tumors. Recent work has demonstrated that CD271 is also involved with MB spinal metastasis [42]. While our study demonstrates that CD271+ cells do invade in vitro, they do not exhibit the highest invasive capacity. Future studies will explore the mechanisms responsible for the higher self-renewal capacity seen in CD271+ cells as well as a potential link between CD271 and Shh signaling in MB.

Another novel finding in our study was the differential expression of genes related to axon guidance in MB tumor spheres and core versus migrating cells. In particular, both ligands and receptors belonging to the EphB-ephrin B pathway were differentially expressed in MB tumor spheres as well as core versus migrating MB cells. Interestingly, global gene expression analysis on higher versus lower self-renewing glioblastoma tumor spheres also revealed differential expression of the same neurodevelopmental pathways, including six Eph-ephrin signaling ligand and receptors (unpublished data). These data support our MB findings and suggest that axon guidance pathways such as Eph-ephrin signaling play a functional role in malignant brain tumor–initiating cell or BTPC populations. The Eph-ephrin signaling pathways play important roles in cellular communication and regulate a variety of aspects during both normal development and disease progression including adhesion, migration, invasion, cell proliferation, survival, and cell morphology through reorganization of the actin cytoskeleton [43,44]. Notably, Eph-ephrin signaling has a well-established role in neurodevelopment [44] and recent studies have even demonstrated that ephrin signaling is regulated by CD271/p75NTR to control axon guidance and mapping [45,46]. This raises the intriguing possibility that Eph signaling and CD271 may be linked in MB as well. While studies have shown that the Eph-ephrin pathway plays an important role in glioma invasion [47–49] and most recently MB invasion in vitro [50], to our knowledge, this is the first study to evaluate the Eph-ephrin signaling expression profile in MB BTPC subpopulations. In fact, few studies have examined the functional role of axon guidance pathways specifically in MB [29]. These pathways may regulate the balance between MB self-renewal and invasion. Recent findings in glioblastoma lend support to this notion, as EphB2 signaling enhanced migration and invasion while decreasing cell proliferation from cells in tumor sphere culture [51].

In addition to Eph-ephrin signaling, our molecular profiling of higher versus lower self-renewing tumor sphere subclones also revealed differences in transcripts associated with the RhoGTPases such as p21 protein (Cdc42/Rac)–activated kinase 3. Although we did not specifically profile the sorted populations (i.e., CD133+/CD271− versus CD133+/CD271+) or the invading cells in our collagen assays, it is possible that the variation in cell motility patterns observed in these gels may also be attributed to differences in axon guidance pathways such as Eph-ephrin signaling and activation of RhoGTPases. Studies are currently underway to evaluate the functional significance of ephrin B–EphB signaling and the RhoGTPases in MB self-renewal versus invasion using our model system.

Combinatory expression of CD271 and CD133 may serve as important selective criteria for drug discovery that will enable concomitant targeting of a spectrum of putative MB-propagating cells and the most highly invasive cells that typically elude current therapies. We are currently pursuing higher throughput flow cytometry technologies to identify other potential cell surface markers that may also select for these transitory phenotypes. This will be important as our studies suggest that drugs targeting cells in the migratory or invasive state may not abrogate the putative TPCs in a state of higher self-renewal.

Acknowledgments
We thank Monroe Chan at the University of Manitoba Flow Cytometry Facility for technical support. We also thank Mark Nachtigal for critical review of the manuscript.

References


Figure W1. CD271 is enriched in tumor sphere culture and highly self-renewing MB subpopulations from multiple cell lines. (A, B) D283 parental adherent cultures grown in 10% FBS (left panels) do not express CD271 but exhibit high levels of CD133 expression by flow cytometry. Following culture as tumor spheres in BTPC conditions, D283 begin to exhibit a small but consistent significant subpopulation of CD271+ cells. CD133 expression is significantly decreased. Insets: live cell–only controls; N = 5 independent experiments. (C, D) CD271 levels (C) are significantly higher in t-hENs relative to normal hENs. CD133 is unchanged t-hENs versus hENs (D); N = 3 independent experiments.
Figure W2. Top diseases, molecular/cellular functions, and networks dysregulated in higher versus lower self-renewing MB tumor spheres. (A) Top diseases (upper panel) and molecular and cellular functions (lower panel) dysregulated in higher self-renewing versus lower self-renewing tumor spheres. (B) Top dysregulated cellular network consisting of molecules associated with cellular movement. Note the presence of EPHB receptors and ephrin B2 ligand. Shaded green areas denote transcripts that are significantly downregulated and red areas denote significantly upregulated transcripts in higher self-renewing versus lower self-renewing tumor spheres.
The Eph-ephrin signaling pathway is dysregulated in migrating versus core MB cells. (A–F) qPCR analysis of the ephrin B2 ligand and EPHB1, B2, B3, B4, and B6 receptors in "core" versus "migrating" Daoy MB cells. Note the up-regulation of ephrin B2, EPHB1, and EPHB2 and significant down-regulation of EPHB3 and EPHB4 in "migrating" versus "core" cells. Error bars, SEM; *P < .05, **P < .01, ***P < .001.

**Table W4.** Primer Sequences Used for qPCR Reactions.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Forward Sequence</th>
<th>Reverse Sequence</th>
<th>Product (bp)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ephrin B2</td>
<td>5′-GTT CGA CAA CAA GTC CCT TTG-3′</td>
<td>5′-CTG AAG CAA TCC CTG ACAA ATA-3′</td>
<td>123</td>
</tr>
<tr>
<td>EPHB1</td>
<td>5′-GGA AAC GGG CTT ATA GCA AAG-3′</td>
<td>5′-TCT CAT CGT AGC CAG AGG TCA ATG-3′</td>
<td>110</td>
</tr>
<tr>
<td>EPHB2</td>
<td>5′-GAC TCC ACT ACA GCG ACT GCT-3′</td>
<td>5′-TCT CAT CGT AGC CAG AGG TCA CCT-3′</td>
<td>82</td>
</tr>
<tr>
<td>EPHB3</td>
<td>5′-TTG TCA ATA CCA TGG ACA AGC-3′</td>
<td>5′-AAT CAC CAA CTG AGG AGA AGG TCA ATG-3′</td>
<td>135</td>
</tr>
<tr>
<td>EPHB4</td>
<td>5′-AAT GTG ACC ACT GAC CGA GAG-3′</td>
<td>5′-ATT TGA CCT CGT AGT CCA GCA-3′</td>
<td>136</td>
</tr>
<tr>
<td>EPHB6</td>
<td>5′-AAT AGC CAC TTG TGT TGC AAG-3′</td>
<td>5′-CAT GAG TAC CAA AAG CTG CCA-3′</td>
<td>144</td>
</tr>
<tr>
<td>Otx2</td>
<td>5′-GAG GTG GCA CTG AAA ATC AAC-3′</td>
<td>5′-TCT TCT TTT TGG CAG TCT TCA-3′</td>
<td>136</td>
</tr>
<tr>
<td>Sox1</td>
<td>5′-TGG ATG AAG GAC AAA GAC CAG-3′</td>
<td>5′-GTT TGT GTT CAG CTA TTG TGT-3′</td>
<td>116</td>
</tr>
<tr>
<td>βIII tubulin</td>
<td>5′-GGC CTT CTT TGG ACA TCT CTT CA-3′</td>
<td>5′-TCG CAG TTA CAC TCC TTC TCC-3′</td>
<td>147</td>
</tr>
</tbody>
</table>

Figure W3. The Eph-ephrin signaling pathway is dysregulated in migrating versus core MB cells. (A–F) qPCR analysis of the ephrin B2 ligand and EPHB1, B2, B3, B4, and B6 receptors in "core" versus "migrating" Daoy MB cells. Note the up-regulation of ephrin B2, EPHB1, and EPHB2 and significant down-regulation of EPHB3 and EPHB4 in "migrating" versus "core" cells. Error bars, SEM; *P < .05, **P < .01, ***P < .001.